Effect of iron chelators on labile iron and oxidative status of thalassaemic erythroid cells

Acta Haematologica

Volumn 123, Issue 1, 2009, Pages 14-20

  Prus, Eugenia ^a   Fibach, Eitan ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Erythropoiesis; Flow cytometry; Iron; Red blood cells; Thalassaemia

Indexed keywords

DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; DEFEROXAMINE MESYLATE; IRON; PHOSPHATIDYLSERINE; REACTIVE OXYGEN METABOLITE;

ARTICLE; BETA THALASSEMIA; CONTROLLED STUDY; DRUG EFFECT; ERYTHROID CELL; ERYTHROID PRECURSOR CELL; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; IRON CHELATION; OXIDATIVE STRESS; PRIORITY JOURNAL; RETICULOCYTE;

BENZOIC ACIDS; BETA-THALASSEMIA; DEFEROXAMINE; ERYTHROCYTES; ERYTHROID CELLS; FERRITINS; FLOW CYTOMETRY; HUMANS; IRON; IRON CHELATING AGENTS; IRON OVERLOAD; OXIDATIVE STRESS; PHOSPHATIDYLSERINES; PYRIDONES; REACTIVE OXYGEN SPECIES; RETICULOCYTES; TRIAZOLES;

EID: 70449671208     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000258958     Document Type: Article

References (37)

1. Kwiatkowski JL, Cohen AR: Iron chelation therapy in sickle-cell disease and other transfusion-dependent anemias. Hematol Oncol Clin North Am 2004; 18: 1355-1377, ix.
2. Taher A: Iron overload in thalassemia and sickle cell disease. Semin Hematology 2005; 42: 5-9.
3. Rund D, Rachmilewitz E: Beta-thalassemia. N Engl J Med 2005; 353: 1135-1146.
4. Beutler E: Iron storage disease: facts, fiction and progress. Blood Cells, Mol Dis 2007; 39: 140-147.
5. Greenberg PL: Myelodysplastic syndromes: iron overload consequences and current chelating therapies. J Natl Compr Canc Netw 2006; 4: 91-96.
6. Wickramasinghe SN: Congenital dyserythropoietic anaemias: clinical features, haematological morphology and new biochemical data. Blood Rev 1998; 12: 178-200.
7. Weatherall DJ: Pathophysiology of thalassaemia. Baillière's Clin Haematol 1998; 11: 127-146.
8. Cappellini MD, Piga A: Current status in iron chelation in hemoglobinopathies. Curr Mol Med 2008; 8: 663-674.
9. Kohen R, Nyska A: Oxidation of biological systems: oxidative stress phenomena, antioxidants, redox reactions, and methods for their quantification. Toxicol Pathol 2002; 30: 620-650.
10. Amer J, Fibach E: Oxidative status of platelets in normal and thalassemic blood. Thromb Haemost 2004; 92: 1052-1059.
11. Jacobs A: Low molecular weight intracellular iron transport compounds. Blood 1977; 50: 433-439.
12. Prus E, Fibach E: The labile iron pool in human erythroid cells. Br J Haematol 2008; 142: 301-307.
13. Amer J, Atlas D, Fibach E: N-acetylcysteine amide (AD4) attenuates oxidative stress in beta-thalassemia blood cells. Biochim Biophys Acta 2008; 1780: 249-255.
14. Fibach E, Manor D, Oppenheim A, Rachmilewitz EA: Proliferation and maturation of human erythroid progenitors in liquid culture. Blood 1989; 73: 100-103.
15. Fibach E, Prus E: Differentiation of human erythroid cells in culture; in Coligan J, Bierer B, Margulies D, Shevach E, Strober W (eds): Current Protocols in Immunology. Edison, John Wiley & Sons, 2005, vol 2 (suppl 69), pp 22.F27.21-10.
16. Prus E, Fibach E: Flow cytometry measurement of the labile iron pool in human hematopoietic cells. Cytometry A 2007; 73: 22-27.
17. Leimberg JM, Prus E, Link G, Fibach E, Konijn AM: Iron-chelator complexes as iron sources for early developing human erythroid precursors. Transl Res 2008; 151: 88-96.
18. Weston SA, Parish CR: New fluorescent dyes for lymphocyte migration studies. Analysis by flow cytometry and fluorescence microscopy. J Immunol Methods 1990; 133: 87-97.
19. Weston SA, Parish CR: Calcein: a novel marker for lymphocytes which enter lymph nodes. Cytometry 1992; 13: 739-749.
20. Breuer W, Epsztejn S, Cabantchik ZI: Iron acquired from transferrin by K562 cells is delivered into a cytoplasmic pool of chelatable iron(II). J Biol Chem 1995; 270: 24209-24215.
21. Petrat F, Weisheit D, Lensen M, De Groot H, Sustmann R, Rauen U: Selective determination of mitochondrial chelatable iron in viable cells with a new fluorescent sensor. Biochem J 2002; 362: 137-147.
22. Baker E, Richardson D, Gross S, Ponka P: Evaluation of the iron chelation potential of hydrazones of pyridoxal, salicylaldehyde and 2-hydroxy-1- naphthylaldehyde using the hepatocyte in culture. Hepatology 1992; 15: 492-501.
23. Crowe WE, Maglova LM, Ponka P, Russell JM: Human cytomegalovirus-induced host cell enlargement is iron dependent. Am J Physiol Cell Physiol 2004; 287: 1023-1030.
24. Epsztejn S, Kakhlon O, Glickstein H, Breuer W, Cabantchik I: Fluorescence analysis of the labile iron pool of mammalian cells. Anal Biochem 1997; 248: 31-40.
25. Amer J, Goldfarb A, Fibach E: Flow cytometric measurement of reactive oxygen species production by normal and thalassaemic red blood cells. Eur J Haematol 2003; 70: 84-90.
26. Bass DA, Parce JW, Dechatelet LR, Szejda P, Seeds MC, Thomas M: Flow cytometric studies of oxidative product formation by neutrophils: a graded response to membrane stimulation. J Immunol 1983; 130: 1910-1917.
27. Koopman G, Reutelingsperger CP, Kuijten GA, Keehnen RM, Pals ST, Van Oers MH: Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood 1994; 84: 1415-1420.
28. Konijn AM, Tal R, Levy R, Matzner Y: Isolation and fractionation of ferritin from human term placenta: a source for human isoferritins. Anal Biochem 1985; 144: 423-428.
29. Loken MR, Shah VO, Dattilio KL, Civin CI: Flow cytometric analysis of human bone marrow. I. Normal erythroid development. Blood 1987; 69: 255-263.
30. Loken MR, Civin CI, Bigbee WL, Langlois RG, Jensen RH: Coordinate glycosylation and cell surface expression of glycophorin A during normal human erythropoiesis. Blood 1987; 70: 1959-1961.
31. Konijn AM, Glickstein H, Vaisman B, Meyron-Holtz EG, Slotki IN, Cabantchik ZI: The cellular labile iron pool and intracellular ferritin in K562 cells. Blood 1999; 94: 2128-2134.
32. Shalev O, Repka T, Goldfarb A, Grinberg L, Abrahamov A, Olivieri NF, Rachmilewitz EA, Hebbel RP: Deferiprone (L1) chelates pathologic iron deposits from membranes of intact thalassemic and sickle red blood cells both in vitro and in vivo. Blood 1995; 86: 2008-2013.
33. Shalev O, Hileti D, Nortey P, Hebbel RP, Hoffbrand VA: Transport of 14C-deferiprone in normal, thalassaemic and sickle red blood cells. Br J Haematol 1999; 105: 1081-1083.
34. Fibach E, Rachmilewitz EA: The two-step liquid culture: a novel procedure for studying maturation of human normal and pathological erythroid precursors. Stem Cells 1993; 11(suppl 1):36-41.
35. Zhang AS, Sheftel AD, Ponka P: Intracellular kinetics of iron in reticulocytes: evidence for endosome involvement in iron targeting to mitochondria. Blood 2005; 105: 368-375.
36. Leimberg J, Prus E, Link G, Fibach E, Konijn A: Iron-chelator complexes as iron sources for early developing human erythroid precursors. Transl Res 2008; 151: 88-96.
37. Kalantar-Zadeh K, Rodriguez RA, Humphreys MH: Association between serum ferritin and measures of inflammation, nutrition and iron in haemodialysis patients. Nephrol Dial Transplant 2004; 19: 141-149.